Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone

Abstract Background Patients with asthma and chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) have more rapid disease progression and more exacerbations than do those with either condition alone. Little research has been performed, however, in these patients. Objective The object...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Value in health 2015-09, Vol.18 (6), p.759-766
Hauptverfasser: Gerhardsson de Verdier, Maria, MD, PhD, Andersson, Maria, PhD, Kern, David M., MS, Zhou, Siting, PhD, Tunceli, Ozgur, PhD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 766
container_issue 6
container_start_page 759
container_title Value in health
container_volume 18
creator Gerhardsson de Verdier, Maria, MD, PhD
Andersson, Maria, PhD
Kern, David M., MS
Zhou, Siting, PhD
Tunceli, Ozgur, PhD
description Abstract Background Patients with asthma and chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) have more rapid disease progression and more exacerbations than do those with either condition alone. Little research has been performed, however, in these patients. Objective The objective was to summarize the health care utilization, costs, and comorbidities of patients with uncontrolled asthma and patients with ACOS. Methods This retrospective analysis used medical and pharmacy claims from large commercial health plans. The study included patients 6 years or older with a diagnosis of asthma and one or more asthma exacerbation (index event). Patients were classified as having asthma alone or ACOS, and the two groups were matched for age, sex, region, index year, index month, and health plan type. Outcomes included rates of comorbid disease, health care utilization, and costs during the 12 months before and after the index exacerbation. Results Among the matched patients with asthma (6,505 ACOS; 26,060 without COPD), mean annual all-cause health care costs were twice as high as for patients with ACOS ($22,393 vs. $11,716; P < 0.0001). Asthma-related costs, representing 29% of total costs, were nearly twice as high among patients with ACOS ($6,319 vs. 3,356; P < 0.0001). Cost differences were driven by large differences in the proportions of patients with an inpatient hospitalization (34.0% vs. 14.6%; P < 0.0001) or emergency department visit (29.6% vs. 19.9%; P < 0.0001). Nearly all prespecified comorbid conditions were more prevalent in the ACOS group. Conclusions Patients with asthma and COPD had nearly double the health care costs as did patients with asthma without COPD. The overall disease profile of patients with asthma should be considered when managing patients, rather than treating asthma as a solitary condition.
doi_str_mv 10.1016/j.jval.2015.04.010
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1717473888</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1098301515019361</els_id><sourcerecordid>1717473888</sourcerecordid><originalsourceid>FETCH-LOGICAL-c525t-d0899694829cd194889640bb409ff1171daeca3df9b746925507cdeb597db6233</originalsourceid><addsrcrecordid>eNp9kU2P0zAQhiMEYpeFP8AB-cglwXbiJEYIqeryJa3UlRbOlmNPVAcnLnZS1H_PhBYOHLh4PPY7rz3PZNlLRgtGWf1mKIaj9gWnTBS0Kiijj7JrJniVV01ZPsY9lW1e4vVV9iylgVJal1w8za54XVFZU36dnTZp3o-a6MmS7T6GyRmy69IcFzO7I5D7xY9h0vFEbl0CnYDsjhC9PpCH02RjGOEtuQ1L5wHrQ5oTruNBR0x_unlP7vXsYMLj39nlsY0PEzzPnvTaJ3hxiTfZt48fvm4_53e7T1-2m7vcCC7m3NJWylpWLZfGMoytxM93HTbQ94w1zGowurS97JqqllwI2hgLnZCN7WpeljfZ67PvIYYfC6RZjS4Z8F5PEJak0KJBXm3bopSfpSaGlCL06hDdiM0rRtWKXA1qRa5W5IpWCpFj0auL_9KNYP-W_GGMgndnAWCXRwdRJYNMDFgXwczKBvd___f_lBvvcEzaf4cTpCEscUJ-iqnEFVUP69DXmTNBmSxrVv4C0-2nxQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1717473888</pqid></control><display><type>article</type><title>Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Gerhardsson de Verdier, Maria, MD, PhD ; Andersson, Maria, PhD ; Kern, David M., MS ; Zhou, Siting, PhD ; Tunceli, Ozgur, PhD</creator><creatorcontrib>Gerhardsson de Verdier, Maria, MD, PhD ; Andersson, Maria, PhD ; Kern, David M., MS ; Zhou, Siting, PhD ; Tunceli, Ozgur, PhD</creatorcontrib><description>Abstract Background Patients with asthma and chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) have more rapid disease progression and more exacerbations than do those with either condition alone. Little research has been performed, however, in these patients. Objective The objective was to summarize the health care utilization, costs, and comorbidities of patients with uncontrolled asthma and patients with ACOS. Methods This retrospective analysis used medical and pharmacy claims from large commercial health plans. The study included patients 6 years or older with a diagnosis of asthma and one or more asthma exacerbation (index event). Patients were classified as having asthma alone or ACOS, and the two groups were matched for age, sex, region, index year, index month, and health plan type. Outcomes included rates of comorbid disease, health care utilization, and costs during the 12 months before and after the index exacerbation. Results Among the matched patients with asthma (6,505 ACOS; 26,060 without COPD), mean annual all-cause health care costs were twice as high as for patients with ACOS ($22,393 vs. $11,716; P &lt; 0.0001). Asthma-related costs, representing 29% of total costs, were nearly twice as high among patients with ACOS ($6,319 vs. 3,356; P &lt; 0.0001). Cost differences were driven by large differences in the proportions of patients with an inpatient hospitalization (34.0% vs. 14.6%; P &lt; 0.0001) or emergency department visit (29.6% vs. 19.9%; P &lt; 0.0001). Nearly all prespecified comorbid conditions were more prevalent in the ACOS group. Conclusions Patients with asthma and COPD had nearly double the health care costs as did patients with asthma without COPD. The overall disease profile of patients with asthma should be considered when managing patients, rather than treating asthma as a solitary condition.</description><identifier>ISSN: 1098-3015</identifier><identifier>EISSN: 1524-4733</identifier><identifier>DOI: 10.1016/j.jval.2015.04.010</identifier><identifier>PMID: 26409602</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Aged ; Anti-Asthmatic Agents - economics ; Anti-Asthmatic Agents - therapeutic use ; asthma ; Asthma - diagnosis ; Asthma - economics ; Asthma - epidemiology ; Asthma - therapy ; Child ; claims data ; Comorbidity ; COPD ; Costs and Cost Analysis ; Disease Progression ; Drug Costs ; Emergency Service, Hospital - economics ; Female ; Health Care Costs ; Health Resources - economics ; Health Resources - utilization ; Hospitalization - economics ; Humans ; Internal Medicine ; Male ; Middle Aged ; Models, Economic ; overlap syndrome ; Prevalence ; Prognosis ; Pulmonary Disease, Chronic Obstructive - complications ; Pulmonary Disease, Chronic Obstructive - economics ; Pulmonary Disease, Chronic Obstructive - epidemiology ; Pulmonary Disease, Chronic Obstructive - therapy ; Retrospective Studies ; Risk Factors ; Syndrome ; Time Factors ; United States - epidemiology ; Young Adult</subject><ispartof>Value in health, 2015-09, Vol.18 (6), p.759-766</ispartof><rights>International Society for Pharmacoeconomics and Outcomes Research (ISPOR)</rights><rights>2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR)</rights><rights>Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c525t-d0899694829cd194889640bb409ff1171daeca3df9b746925507cdeb597db6233</citedby><cites>FETCH-LOGICAL-c525t-d0899694829cd194889640bb409ff1171daeca3df9b746925507cdeb597db6233</cites><orcidid>0000-0003-1968-6551</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jval.2015.04.010$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26409602$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gerhardsson de Verdier, Maria, MD, PhD</creatorcontrib><creatorcontrib>Andersson, Maria, PhD</creatorcontrib><creatorcontrib>Kern, David M., MS</creatorcontrib><creatorcontrib>Zhou, Siting, PhD</creatorcontrib><creatorcontrib>Tunceli, Ozgur, PhD</creatorcontrib><title>Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone</title><title>Value in health</title><addtitle>Value Health</addtitle><description>Abstract Background Patients with asthma and chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) have more rapid disease progression and more exacerbations than do those with either condition alone. Little research has been performed, however, in these patients. Objective The objective was to summarize the health care utilization, costs, and comorbidities of patients with uncontrolled asthma and patients with ACOS. Methods This retrospective analysis used medical and pharmacy claims from large commercial health plans. The study included patients 6 years or older with a diagnosis of asthma and one or more asthma exacerbation (index event). Patients were classified as having asthma alone or ACOS, and the two groups were matched for age, sex, region, index year, index month, and health plan type. Outcomes included rates of comorbid disease, health care utilization, and costs during the 12 months before and after the index exacerbation. Results Among the matched patients with asthma (6,505 ACOS; 26,060 without COPD), mean annual all-cause health care costs were twice as high as for patients with ACOS ($22,393 vs. $11,716; P &lt; 0.0001). Asthma-related costs, representing 29% of total costs, were nearly twice as high among patients with ACOS ($6,319 vs. 3,356; P &lt; 0.0001). Cost differences were driven by large differences in the proportions of patients with an inpatient hospitalization (34.0% vs. 14.6%; P &lt; 0.0001) or emergency department visit (29.6% vs. 19.9%; P &lt; 0.0001). Nearly all prespecified comorbid conditions were more prevalent in the ACOS group. Conclusions Patients with asthma and COPD had nearly double the health care costs as did patients with asthma without COPD. The overall disease profile of patients with asthma should be considered when managing patients, rather than treating asthma as a solitary condition.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Anti-Asthmatic Agents - economics</subject><subject>Anti-Asthmatic Agents - therapeutic use</subject><subject>asthma</subject><subject>Asthma - diagnosis</subject><subject>Asthma - economics</subject><subject>Asthma - epidemiology</subject><subject>Asthma - therapy</subject><subject>Child</subject><subject>claims data</subject><subject>Comorbidity</subject><subject>COPD</subject><subject>Costs and Cost Analysis</subject><subject>Disease Progression</subject><subject>Drug Costs</subject><subject>Emergency Service, Hospital - economics</subject><subject>Female</subject><subject>Health Care Costs</subject><subject>Health Resources - economics</subject><subject>Health Resources - utilization</subject><subject>Hospitalization - economics</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Models, Economic</subject><subject>overlap syndrome</subject><subject>Prevalence</subject><subject>Prognosis</subject><subject>Pulmonary Disease, Chronic Obstructive - complications</subject><subject>Pulmonary Disease, Chronic Obstructive - economics</subject><subject>Pulmonary Disease, Chronic Obstructive - epidemiology</subject><subject>Pulmonary Disease, Chronic Obstructive - therapy</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Syndrome</subject><subject>Time Factors</subject><subject>United States - epidemiology</subject><subject>Young Adult</subject><issn>1098-3015</issn><issn>1524-4733</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU2P0zAQhiMEYpeFP8AB-cglwXbiJEYIqeryJa3UlRbOlmNPVAcnLnZS1H_PhBYOHLh4PPY7rz3PZNlLRgtGWf1mKIaj9gWnTBS0Kiijj7JrJniVV01ZPsY9lW1e4vVV9iylgVJal1w8za54XVFZU36dnTZp3o-a6MmS7T6GyRmy69IcFzO7I5D7xY9h0vFEbl0CnYDsjhC9PpCH02RjGOEtuQ1L5wHrQ5oTruNBR0x_unlP7vXsYMLj39nlsY0PEzzPnvTaJ3hxiTfZt48fvm4_53e7T1-2m7vcCC7m3NJWylpWLZfGMoytxM93HTbQ94w1zGowurS97JqqllwI2hgLnZCN7WpeljfZ67PvIYYfC6RZjS4Z8F5PEJak0KJBXm3bopSfpSaGlCL06hDdiM0rRtWKXA1qRa5W5IpWCpFj0auL_9KNYP-W_GGMgndnAWCXRwdRJYNMDFgXwczKBvd___f_lBvvcEzaf4cTpCEscUJ-iqnEFVUP69DXmTNBmSxrVv4C0-2nxQ</recordid><startdate>20150901</startdate><enddate>20150901</enddate><creator>Gerhardsson de Verdier, Maria, MD, PhD</creator><creator>Andersson, Maria, PhD</creator><creator>Kern, David M., MS</creator><creator>Zhou, Siting, PhD</creator><creator>Tunceli, Ozgur, PhD</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1968-6551</orcidid></search><sort><creationdate>20150901</creationdate><title>Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone</title><author>Gerhardsson de Verdier, Maria, MD, PhD ; Andersson, Maria, PhD ; Kern, David M., MS ; Zhou, Siting, PhD ; Tunceli, Ozgur, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c525t-d0899694829cd194889640bb409ff1171daeca3df9b746925507cdeb597db6233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Anti-Asthmatic Agents - economics</topic><topic>Anti-Asthmatic Agents - therapeutic use</topic><topic>asthma</topic><topic>Asthma - diagnosis</topic><topic>Asthma - economics</topic><topic>Asthma - epidemiology</topic><topic>Asthma - therapy</topic><topic>Child</topic><topic>claims data</topic><topic>Comorbidity</topic><topic>COPD</topic><topic>Costs and Cost Analysis</topic><topic>Disease Progression</topic><topic>Drug Costs</topic><topic>Emergency Service, Hospital - economics</topic><topic>Female</topic><topic>Health Care Costs</topic><topic>Health Resources - economics</topic><topic>Health Resources - utilization</topic><topic>Hospitalization - economics</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Models, Economic</topic><topic>overlap syndrome</topic><topic>Prevalence</topic><topic>Prognosis</topic><topic>Pulmonary Disease, Chronic Obstructive - complications</topic><topic>Pulmonary Disease, Chronic Obstructive - economics</topic><topic>Pulmonary Disease, Chronic Obstructive - epidemiology</topic><topic>Pulmonary Disease, Chronic Obstructive - therapy</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Syndrome</topic><topic>Time Factors</topic><topic>United States - epidemiology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gerhardsson de Verdier, Maria, MD, PhD</creatorcontrib><creatorcontrib>Andersson, Maria, PhD</creatorcontrib><creatorcontrib>Kern, David M., MS</creatorcontrib><creatorcontrib>Zhou, Siting, PhD</creatorcontrib><creatorcontrib>Tunceli, Ozgur, PhD</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Value in health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gerhardsson de Verdier, Maria, MD, PhD</au><au>Andersson, Maria, PhD</au><au>Kern, David M., MS</au><au>Zhou, Siting, PhD</au><au>Tunceli, Ozgur, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone</atitle><jtitle>Value in health</jtitle><addtitle>Value Health</addtitle><date>2015-09-01</date><risdate>2015</risdate><volume>18</volume><issue>6</issue><spage>759</spage><epage>766</epage><pages>759-766</pages><issn>1098-3015</issn><eissn>1524-4733</eissn><abstract>Abstract Background Patients with asthma and chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) have more rapid disease progression and more exacerbations than do those with either condition alone. Little research has been performed, however, in these patients. Objective The objective was to summarize the health care utilization, costs, and comorbidities of patients with uncontrolled asthma and patients with ACOS. Methods This retrospective analysis used medical and pharmacy claims from large commercial health plans. The study included patients 6 years or older with a diagnosis of asthma and one or more asthma exacerbation (index event). Patients were classified as having asthma alone or ACOS, and the two groups were matched for age, sex, region, index year, index month, and health plan type. Outcomes included rates of comorbid disease, health care utilization, and costs during the 12 months before and after the index exacerbation. Results Among the matched patients with asthma (6,505 ACOS; 26,060 without COPD), mean annual all-cause health care costs were twice as high as for patients with ACOS ($22,393 vs. $11,716; P &lt; 0.0001). Asthma-related costs, representing 29% of total costs, were nearly twice as high among patients with ACOS ($6,319 vs. 3,356; P &lt; 0.0001). Cost differences were driven by large differences in the proportions of patients with an inpatient hospitalization (34.0% vs. 14.6%; P &lt; 0.0001) or emergency department visit (29.6% vs. 19.9%; P &lt; 0.0001). Nearly all prespecified comorbid conditions were more prevalent in the ACOS group. Conclusions Patients with asthma and COPD had nearly double the health care costs as did patients with asthma without COPD. The overall disease profile of patients with asthma should be considered when managing patients, rather than treating asthma as a solitary condition.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26409602</pmid><doi>10.1016/j.jval.2015.04.010</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-1968-6551</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1098-3015
ispartof Value in health, 2015-09, Vol.18 (6), p.759-766
issn 1098-3015
1524-4733
language eng
recordid cdi_proquest_miscellaneous_1717473888
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ScienceDirect Journals (5 years ago - present)
subjects Adolescent
Adult
Aged
Anti-Asthmatic Agents - economics
Anti-Asthmatic Agents - therapeutic use
asthma
Asthma - diagnosis
Asthma - economics
Asthma - epidemiology
Asthma - therapy
Child
claims data
Comorbidity
COPD
Costs and Cost Analysis
Disease Progression
Drug Costs
Emergency Service, Hospital - economics
Female
Health Care Costs
Health Resources - economics
Health Resources - utilization
Hospitalization - economics
Humans
Internal Medicine
Male
Middle Aged
Models, Economic
overlap syndrome
Prevalence
Prognosis
Pulmonary Disease, Chronic Obstructive - complications
Pulmonary Disease, Chronic Obstructive - economics
Pulmonary Disease, Chronic Obstructive - epidemiology
Pulmonary Disease, Chronic Obstructive - therapy
Retrospective Studies
Risk Factors
Syndrome
Time Factors
United States - epidemiology
Young Adult
title Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T09%3A44%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Asthma%20and%20Chronic%20Obstructive%20Pulmonary%20Disease%20Overlap%20Syndrome:%20Doubled%20Costs%20Compared%20with%20Patients%20with%20Asthma%20Alone&rft.jtitle=Value%20in%20health&rft.au=Gerhardsson%20de%20Verdier,%20Maria,%20MD,%20PhD&rft.date=2015-09-01&rft.volume=18&rft.issue=6&rft.spage=759&rft.epage=766&rft.pages=759-766&rft.issn=1098-3015&rft.eissn=1524-4733&rft_id=info:doi/10.1016/j.jval.2015.04.010&rft_dat=%3Cproquest_cross%3E1717473888%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1717473888&rft_id=info:pmid/26409602&rft_els_id=S1098301515019361&rfr_iscdi=true